These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15198465)

  • 21. Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics.
    Watanabe A; Shibata I; Kato T
    Psychiatry Clin Neurosci; 2004 Jun; 58(3):268-73. PubMed ID: 15149292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of life in the long-term treatment and the role of second-generation antipsychotics.
    Mohr P
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():117-33. PubMed ID: 17262004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
    Volavka J; Citrome L
    Expert Opin Pharmacother; 2009 Aug; 10(12):1917-28. PubMed ID: 19558339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
    Chakos M; Lieberman J; Hoffman E; Bradford D; Sheitman B
    Am J Psychiatry; 2001 Apr; 158(4):518-26. PubMed ID: 11282684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What are we looking for in new antipsychotics?
    Correll CU
    J Clin Psychiatry; 2011; 72 Suppl 1():9-13. PubMed ID: 22217437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
    Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
    Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New generation vs. first generation antipsychotics debate: pragmatic clinical trials and practice-based evidence.
    Jakovljević M
    Psychiatr Danub; 2009 Dec; 21(4):446-52. PubMed ID: 19935477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical effectiveness of new generation antipsychotics in adolescent patients.
    Arango C; Parellada M; Moreno DM
    Eur Neuropsychopharmacol; 2004 Nov; 14 Suppl 4():S471-9. PubMed ID: 15572266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics.
    Nakonezny PA; Byerly MJ
    Schizophr Res; 2006 Feb; 82(1):107-14. PubMed ID: 16376522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First- and second-generation antipsychotics: learning from CUtLASS and CATIE.
    Tandon R; Carpenter WT; Davis JM
    Arch Gen Psychiatry; 2007 Aug; 64(8):977-8; author reply 979-80. PubMed ID: 17679642
    [No Abstract]   [Full Text] [Related]  

  • 31. Adherence to medication and quality of life in people with schizophrenia: results of a European multicenter study.
    Puschner B; Born A; Giessler A; Helm H; Leese M; Bindman JP; Gray RJ; Schene A; Kikkert M; Burti L; Marrella G; Becker T
    J Nerv Ment Dis; 2006 Oct; 194(10):746-52. PubMed ID: 17041286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia].
    Samalin L; Ben Gharbia M; Garnier M; Llorca PM
    Encephale; 2014 Dec; 40(6):507-17. PubMed ID: 25453735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antipsychotics and the quality of life of schizophrenic patients.
    Loga-Zec S; Loga S
    Psychiatr Danub; 2010 Dec; 22(4):495-7. PubMed ID: 21169888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey.
    McGrath BM; Tempier RP
    Pharmacopsychiatry; 2005 Jul; 38(4):147-57. PubMed ID: 16025416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects.
    Hofer A; Kemmler G; Eder U; Edlinger M; Hummer M; Fleischhacker WW
    J Clin Psychiatry; 2004 Jul; 65(7):932-9. PubMed ID: 15291682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia.
    Keith SJ; Pani L; Nick B; Emsley R; San L; Turner M; Conley R; Scully P; Chue PS; Lachaux B
    Psychiatr Serv; 2004 Sep; 55(9):997-1005. PubMed ID: 15345759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission.
    Yen CF; Cheng CP; Huang CF; Yen JY; Ko CH; Chen CS
    Bipolar Disord; 2008 Jul; 10(5):617-24. PubMed ID: 18657246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life and new antipsychotics in schizophrenia. Are patients better off?
    Awad AG; Voruganti LN
    Int J Soc Psychiatry; 1999; 45(4):268-75. PubMed ID: 10689610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
    Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
    J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.